Characteristics and Disease Burden of Patients With Eosinophilic Granulomatosis With Polyangiitis Initiating Mepolizumab in the United States.
Journal
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
ISSN: 1536-7355
Titre abrégé: J Clin Rheumatol
Pays: United States
ID NLM: 9518034
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
medline:
21
11
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
ppublish
Résumé
Although the high disease burden associated with eosinophilic granulomatosis with polyangiitis (EGPA) has been established, the disease burden in patients initiating mepolizumab in real-world practice is poorly understood. This study aimed to assess characteristics and burden of real-world patients with EGPA initiating mepolizumab. This was a database study (GSK study ID: 214156) of US patients (≥12 years old) with EGPA and ≥1 mepolizumab claim (index date) identified from the Merative MarketScan Commercial and Medicare Supplemental Databases (November 1, 2015, to March 31, 2020). Outcomes assessed in the 12-month baseline period before index (inclusive) included patient characteristics, treatment use, EGPA relapses, asthma exacerbations, health care resource utilization, and costs. In the 103 patients included (mean age, 51.1 years; 63.1% female), the most common manifestations were asthma (89.3%), chronic sinusitis (57.3%), and allergic rhinitis (43.7%). In total, 91.3% of patients had ≥1 oral corticosteroid (OCS) claim (median dose, 7.4 mg/d prednisone-equivalent), 45.6% were chronic OCS users (≥10 mg/d during the 90 days preindex), 99.0% had ≥1 EGPA-related relapse, and 62.1% ≥1 asthma exacerbation. During the baseline period, 26.2% and 97.1% of patients had EGPA-related inpatient admissions and office visits, respectively. Median all-cause total health care costs per patient were $33,298, with total outpatient costs ($16,452) representing the largest driver. Before initiating mepolizumab, a substantial real-world EGPA disease burden is evident for patients, with resulting impact on health care systems, and indicative of unmet medical needs. Mepolizumab treatment, with a demonstrated positive clinical benefit-risk profile may represent a useful treatment option for reducing EGPA disease burden.
Sections du résumé
BACKGROUND/OBJECTIVE
OBJECTIVE
Although the high disease burden associated with eosinophilic granulomatosis with polyangiitis (EGPA) has been established, the disease burden in patients initiating mepolizumab in real-world practice is poorly understood. This study aimed to assess characteristics and burden of real-world patients with EGPA initiating mepolizumab.
METHODS
METHODS
This was a database study (GSK study ID: 214156) of US patients (≥12 years old) with EGPA and ≥1 mepolizumab claim (index date) identified from the Merative MarketScan Commercial and Medicare Supplemental Databases (November 1, 2015, to March 31, 2020). Outcomes assessed in the 12-month baseline period before index (inclusive) included patient characteristics, treatment use, EGPA relapses, asthma exacerbations, health care resource utilization, and costs.
RESULTS
RESULTS
In the 103 patients included (mean age, 51.1 years; 63.1% female), the most common manifestations were asthma (89.3%), chronic sinusitis (57.3%), and allergic rhinitis (43.7%). In total, 91.3% of patients had ≥1 oral corticosteroid (OCS) claim (median dose, 7.4 mg/d prednisone-equivalent), 45.6% were chronic OCS users (≥10 mg/d during the 90 days preindex), 99.0% had ≥1 EGPA-related relapse, and 62.1% ≥1 asthma exacerbation. During the baseline period, 26.2% and 97.1% of patients had EGPA-related inpatient admissions and office visits, respectively. Median all-cause total health care costs per patient were $33,298, with total outpatient costs ($16,452) representing the largest driver.
CONCLUSIONS
CONCLUSIONS
Before initiating mepolizumab, a substantial real-world EGPA disease burden is evident for patients, with resulting impact on health care systems, and indicative of unmet medical needs. Mepolizumab treatment, with a demonstrated positive clinical benefit-risk profile may represent a useful treatment option for reducing EGPA disease burden.
Identifiants
pubmed: 37779234
doi: 10.1097/RHU.0000000000002033
pii: 00124743-990000000-00159
pmc: PMC10662597
doi:
Substances chimiques
mepolizumab
90Z2UF0E52
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-387Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Allergol Int. 2019 Oct;68(4):430-436
pubmed: 31266709
Autoimmun Rev. 2015 Apr;14(4):341-8
pubmed: 25500434
Clin Ther. 2011 Oct;33(10):1413-32
pubmed: 21999885
Clin Microbiol Infect. 2010 Jun;16(6):715-21
pubmed: 19614717
Arthritis Rheum. 2013 Jan;65(1):270-81
pubmed: 23044708
Rheumatol Adv Pract. 2018 Feb 21;2(1):rky005
pubmed: 31431954
J Rheumatol. 2015 Dec;42(12):2383-91
pubmed: 26523026
Ann Rheum Dis. 2016 Jun;75(6):952-7
pubmed: 26933146
N Engl J Med. 2017 May 18;376(20):1921-1932
pubmed: 28514601
Mod Rheumatol. 2022 Feb 28;32(2):380-386
pubmed: 34894250
Arthritis Rheum. 2001 Mar;44(3):666-75
pubmed: 11263782
Rheumatology (Oxford). 2015 Mar;54(3):471-81
pubmed: 25205825
Psychother Psychosom. 2022;91(1):8-35
pubmed: 34991091
Arthritis Rheumatol. 2021 Aug;73(8):1366-1383
pubmed: 34235894
J Asthma. 2023 Apr;60(4):811-823
pubmed: 35853158
J Rheumatol. 2021 Mar;48(3):385-393
pubmed: 32611669
Ann Rheum Dis. 2013 Jun;72(6):1011-7
pubmed: 22887848
Rhinology. 2015 Sep;53(3):277-85
pubmed: 26363169
J Clin Rheumatol. 2021 Apr 1;27(3):107-113
pubmed: 31693654
Ann Rheum Dis. 2022 Mar;81(3):309-314
pubmed: 35110334
Front Med (Lausanne). 2021 Feb 24;8:627776
pubmed: 33718405
Clin Rheumatol. 2021 Dec;40(12):4829-4836
pubmed: 34159493
Am J Respir Crit Care Med. 2020 Feb 1;201(3):276-293
pubmed: 31525297
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Rheumatology (Oxford). 2022 Oct 6;61(10):3930-3938
pubmed: 35078225
Clin Exp Rheumatol. 2015 Mar-Apr;33(2 Suppl 89):S-11-8
pubmed: 25437862
J Manag Care Spec Pharm. 2021 Sep;27(9):1249-1259
pubmed: 34165321
Ann Rheum Dis. 2023 Mar 16;:
pubmed: 36927642
Lupus Sci Med. 2022 May;9(1):
pubmed: 35609952
Drugs. 2018 Jun;78(8):809-821
pubmed: 29766394